Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064415 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 799
- Enrollment target
NCT00064415: Completed Phase 3 study, sponsored by Sumitomo Pharma America.
NCT00064415 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 799 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064415, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 799 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
Interventions
- DRUG Salmeterol
- DRUG arformoterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 799 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
What the finished NCT00064415 record still lists
NCT00064415 is an interventional study that assigns participants to a tested intervention. The registered 799 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Salmeterol is the first listed.
NCT00064415 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00064415 about?
NCT00064415 is a clinical study titled "To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD". The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
What is the current status of trial NCT00064415?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 799 participants. The study started on 2002-06. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00064415?
The interventions under investigation include: Salmeterol (DRUG), arformoterol (DRUG).
Who is sponsoring clinical trial NCT00064415?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00064415's enrollment target sits among peer trials
799 428th of 2000 higher than 1,573 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia